Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience

Transcriptase Inhibitor ◽

Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients

AIDS ◽

10.1097/00002030-200005050-00004 ◽

2000 ◽

Vol 14 (7) ◽

pp. 791-799 ◽

Cited By ~ 26

Author(s):

Nina Khanna ◽

Thomas Klimkait ◽

Veronique Schiffer ◽

Jose Irigoyen ◽

Amalio Telenti ◽

...

Keyword(s):

Protease Inhibitor ◽

Reverse Transcriptase ◽

Salvage Therapy ◽

Transcriptase Inhibitor ◽

Reverse Transcriptase Inhibitor ◽

Hiv 1

Immune Reconstitution Is Comparable in Antiretroviral‐Naive Subjects after 1 Year of Successful Therapy with a Nucleoside Reverse‐Transcriptase Inhibitor– or Protease Inhibitor–Containing Antiretroviral Regimen

The Journal of Infectious Diseases ◽

10.1086/379041 ◽

2003 ◽

Vol 188 (10) ◽

pp. 1444-1454 ◽

Cited By ~ 24

Author(s):

Alan L. Landay ◽

John Spritzler ◽

Harold Kessler ◽

Donna Mildvan ◽

Minya Pu ◽

...

Keyword(s):

Protease Inhibitor ◽

Reverse Transcriptase ◽

Immune Reconstitution ◽

Transcriptase Inhibitor ◽

Successful Therapy ◽

Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals

Journal of Antimicrobial Chemotherapy ◽

10.1093/jac/dkq432 ◽

2010 ◽

Vol 66 (2) ◽

pp. 358-362 ◽

Cited By ~ 14

Author(s):

A. Imaz ◽

J. M. Llibre ◽

M. Mora ◽

G. Mateo ◽

A. Camacho ◽

...

Keyword(s):

Reverse Transcriptase ◽

Salvage Therapy ◽

Transcriptase Inhibitor ◽

Multidrug Resistant ◽

Efficacy And Safety ◽

New Class ◽

New Generation ◽

Reverse Transcriptase Inhibitor ◽

Hiv 1

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial

The Lancet ◽

10.1016/s0140-6736(06)69074-0 ◽

2006 ◽

Vol 368 (9532) ◽

pp. 287-298 ◽

Cited By ~ 60

Keyword(s):

Antiretroviral Therapy ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Randomised Trial ◽

Transcriptase Inhibitor ◽

Open Label ◽

Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060

PLoS ONE ◽

10.1371/journal.pone.0165140 ◽

2016 ◽

Vol 11 (12) ◽

pp. e0165140 ◽

Cited By ~ 8

Author(s):

Charlotte V. Hobbs ◽

Erin E. Gabriel ◽

Portia Kamthunzi ◽

Gerald Tegha ◽

Jean Tauzie ◽

...

Keyword(s):

Antiretroviral Therapy ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

Hiv Protease ◽

Hiv Protease Inhibitor ◽

The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment – results from an observational study in Germany

Journal of Pharmaceutical Policy and Practice ◽

10.1186/s40545-016-0092-4 ◽

2016 ◽

Vol 9 (1) ◽

Cited By ~ 1

Author(s):

Jörg Mahlich ◽

Mona Groß ◽

Alexander Kuhlmann ◽

Johannes Bogner ◽

Hans Heiken ◽

...

Keyword(s):

Observational Study ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Antiretroviral Treatment ◽

Transcriptase Inhibitor ◽

Treatment Results ◽

Second-line protease inhibitor-based highly active antiretroviral therapy after failing non-nucleoside reverse transcriptase inhibitor-based regimens in Asian HIV-infected children

Antiviral Therapy ◽

10.3851/imp2494 ◽

2013 ◽

Vol 18 (4) ◽

pp. 591-598 ◽

Cited By ~ 8

Author(s):

Torsak Bunupuradah ◽

◽

Thanyawee Puthanakit ◽

Paul Fahey ◽

Azar Kariminia ◽

...

Keyword(s):

Antiretroviral Therapy ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Highly Active Antiretroviral Therapy ◽

Transcriptase Inhibitor ◽

Second Line ◽

Highly Active ◽

An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma

Journal of Chromatography B ◽

10.1016/j.jchromb.2006.10.022 ◽

2007 ◽

Vol 848 (2) ◽

pp. 369-373 ◽

Cited By ~ 32

Author(s):

Dennis R. Weller ◽

Richard C. Brundage ◽

Henry H. Balfour ◽

Heather E. Vezina

Keyword(s):

Liquid Chromatography ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Human Plasma ◽

Transcriptase Inhibitor ◽

Chromatography Method ◽

Liquid Chromatography Method ◽

Response to comments on the comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-containing regimens using observational databases

AIDS ◽

10.1097/00002030-200201250-00027 ◽

2002 ◽

Vol 16 (2) ◽

pp. 302-303

Author(s):

Azra C. Ghani ◽

William E. Henley ◽

Christl A. Donnelly ◽

Steven Mayer ◽

Roy M. Anderson

Keyword(s):

Protease Inhibitor ◽

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens

AIDS ◽

10.1097/00002030-200305020-00026 ◽

2003 ◽

Vol 17 (7) ◽

pp. 1099-1102 ◽

Cited By ~ 44

Author(s):

Maria Paola Trotta ◽

Adriana Ammassari ◽

Alessandro Cozzi-Lepri ◽

Mauro Zaccarelli ◽

Francesco Castelli ◽

...

Keyword(s):

Antiretroviral Therapy ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Highly Active Antiretroviral Therapy ◽

Transcriptase Inhibitor ◽

Highly Active ◽